Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma



Status:Not yet recruiting
Conditions:Lymphoma, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/1/2019
Start Date:March 2019
End Date:August 2022
Contact:TG Therapeutics Clinical Support Team
Email:clinicalsupport@tgtxinc.com
Phone:212-554-4484

Use our guide to learn which trials are right for you!

A Phase 1 Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma

Phase 1 open label, single-arm, multi-center, dose-escalation study for individuals with
relapsed or refractory classical Hodgkin's Lymphoma or B-cell Non Hodgkin's Lymphoma.

Planned enrollment includes 3 subjects at each dose level. TG-1501 will be administered as a
60-minute IV infusion at fixed dose levels on Days 1 and 15 of every 28-day cycle or only on
Day 1 of every 28-day cycle.

Inclusion Criteria:

- Histologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL) or
B-cell non-Hodgkin lymphoma (NHL).

- Measurable disease and adequate organ function as specified in the protocol

- Life expectancy of at least 3 months

Exclusion Criteria:

- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, antibody, or any other
antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint
pathways.

- Subjects receiving cancer therapy or investigational drug within 21 days of Cycle 1
Day 1.

- Prior autologous stem cell transplant within 3 months

- Active Hepatitis B or Hepatitis C
We found this trial at
1
site
Charlotte, North Carolina 28211
?
mi
from
Charlotte, NC
Click here to add this to my saved trials